TRATAMIENTO ANTICOAGULANTE EN PACIENTES CON FIBRILACIÓN AURICULAR Y ENFERMEDAD RENAL CRÓNICA

Abstract

Introduction. Atrial fibrillation is the most common arrhythmia characterized by premature atrial beats, causing ineffective atrial contraction and promoting thrombus formation. It is associated with chronic kidney disease, where a prothrombotic and prohemorrhagic state coexists, further increasing thromboembolic risk. Treatment with oral anticoagulants is key to preventing thromboembolic events. Objective. To analyze the clinical benefit of oral anticoagulant therapy in patients with non-valvular AF and advanced CKD. Methodology. A bibliographic review was conducted in the MEDLINE/PubMed, Scopus, and ScienceDirect databases. The review included articles published in the last 5 years, open access, and in English or Spanish. Results. The reviewed studies indicate the need to properly stratify thromboembolic and hemorrhagic risk. DOACs are the anticoagulant therapy of choice over warfarin, except in moderate to severe mitral stenoses and in patients with mechanical prosthetic valves. The recommendations and evidence for advanced CKD and dialysis are unclear, especially when CrCl <15 ml/min. Furthermore, factors that could influence therapy, such as the presence of polypharmacy and the assessment of renal function, should be considered. Conclusion. The evidence does not suggest a benefit of oral anticoagulant therapy in preventing thromboembolism in patients with advanced CKD, and alternative non-pharmacological therapies could be chosen.